Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase
Journal of Viral Hepatitis · 2024-12 · 31 (S2) · 27-35
DOI: 10.1111/jvh.13914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 08.05.2024. Verfasst von Lung-Yi Mak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Special Administrative Region, China. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatitis B virus (HBV) infection is a dynamic disease where patients progress through several stages defined by HBV e‐antigen (HBeAg) status, HBV‐DNA levels and transaminase elevations, with antiviral therapy indicated only in specific stages. However, some patients cannot be classified into one of the stages and are said to fall into an ‘indeterminate phase’ or ‘grey zone’. Exact definitions of the indeterminate phase vary from guideline to guideline as a result of different cut‐off values for biomarker measurements. Data suggest that as many as 50% of HBV patients may be in an indeterminate phase and may not rapidly transition out of this phase. Clinical data that suggest these patients are at increased risk of hepatocellular carcinoma (HCC) are complemented by molecular evidence of integrations of HBV‐DNA into the host genome, chromosomal translocations and immune activation despite liver enzymes that may suggest lack of inflammation. Antiviral therapy reduces these hepatocarcinogenic mechanisms and is reflected in a reduction of fibrosis and HCC risk. We review key data on patients in the indeterminate phase, with emphasis on HCC as an outcome. We take a holistic approach and link new biological data with clinical observations as well as examine the potential role of antiviral therapy in reducing HCC risk among patients in the indeterminate phase. With the availability of safe and effective oral antivirals, consideration must be given as to how much residual risk of HCC should be tolerated among patients in the indeterminate phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Special Administrative Region, China.
- Gilead Sciences, Foster City, California, USA.
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
- Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
- Laura Rodriguez Research Institute, Family Health Centers of San Diego, San Diego, California, USA.
- University of California, San Diego School of Medicine, La Jolla, California, USA.
ORCID-Profile: Lung-Yi Mak, Leland J Yee, Robert J Wong, Yao-Chun Hsu
Zitieren
APA
Mak, L. Y., Yee, L. J., Wong, R. J., Ramers, C. B., Frenette, C., & Hsu, Y. C. (2024). Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase. Journal of Viral Hepatitis, 31(S2), 27-35. https://doi.org/10.1111/jvh.13914
Vancouver
Mak LY, Yee LJ, Wong RJ, Ramers CB, Frenette C, Hsu YC. Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase. Journal of Viral Hepatitis. 2024;31(S2):27-35. doi:10.1111/jvh.13914
BibTeX
@article{Mak2024,
author = {Mak, Lung-Yi and Yee, Leland J and Wong, Robert J and Ramers, Christian B and Frenette, Catherine and Hsu, Yao-Chun},
title = {Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase},
journal = {Journal of Viral Hepatitis},
year = {2024},
volume = {31},
number = {S2},
pages = {27--35},
doi = {10.1111/jvh.13914}
}
EUVIMED